Relay Therapeutics (RLAY) Operating Leases (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Operating Leases of $27.7 million for Q1 2026, down 32.87% year-over-year from $41.2 million in Q1 2025, and down 3.53% quarter-over-quarter from $28.7 million in Q4 2025.
Relay Therapeutics (RLAY) Operating Leases (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Operating Leases for 8 consecutive years, with $27.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 32.87% year-over-year to $27.7 million; the TTM figure through Mar 2026 stood at $27.7 million (down 32.87% YoY), while the FY2025 annual figure was $28.7 million, down 32.92% from the prior year.
- Operating Leases retreated to $27.7 million in Q1 2026 per RLAY's latest filing, from $28.7 million in the prior quarter.
- Across five years, Operating Leases topped out at $54.6 million in Q3 2022 and bottomed at $20.0 million in Q2 2022.
- Historically, Operating Leases has averaged $40.5 million across 5 years, with a median of $44.3 million in 2024.
- Annual changes were most pronounced in 2023 — Operating Leases jumped 155.25% — and 2025, when it plunged 33.01%.
- Relay Therapeutics' Operating Leases stood at $53.5 million in 2022, then fell by 9.28% to $48.5 million in 2023, then slipped by 11.81% to $42.8 million in 2024, then plunged by 32.92% to $28.7 million in 2025, then decreased by 3.53% to $27.7 million in 2026.
- Business Quant data shows RLAY's Operating Leases at $27.7 million in Q1 2026, $28.7 million in Q4 2025, and $29.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.64 Mn |
| Mar 31, 2026 | 27.68 Mn |
| Dec 31, 2025 | 28.69 Mn |
| Sep 30, 2025 | 29.69 Mn |
| Jun 30, 2025 | 30.66 Mn |
| Mar 31, 2025 | 41.23 Mn |
| Dec 31, 2024 | 42.78 Mn |
| Sep 30, 2024 | 44.29 Mn |
| Jun 30, 2024 | 45.76 Mn |
| Mar 31, 2024 | 47.16 Mn |
| Dec 31, 2023 | 48.50 Mn |
| Sep 30, 2023 | 49.82 Mn |
| Jun 30, 2023 | 51.10 Mn |
| Mar 31, 2023 | 52.31 Mn |
| Dec 31, 2022 | 53.47 Mn |
| Sep 30, 2022 | 54.60 Mn |
| Jun 30, 2022 | 20.02 Mn |
| Mar 31, 2022 | 20.56 Mn |
| Dec 31, 2021 | 21.06 Mn |
| Sep 30, 2021 | 21.55 Mn |